Peritoneal plantation inhibitor, peritoneal plantation inhibition method, peritoneal plantation prevention method, and peritoneal plantation treatment method

By using adeno-associated virus vectors to deliver miR-29b, the problem of effective inhibition of peritoneal implantation was solved, and the effect of highly efficient inhibition of peritoneal implantation in vivo was achieved, especially a significant reduction in peritoneal implantation nodules on the mesentery.

CN120731090APending Publication Date: 2025-09-30JICHI MEDICAL UNIVERSITY
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202380089563.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-12-28
Filing Date
2023-12-14
Publication Date
2025-09-30

AI Technical Summary

Technical Problem

Existing technologies are unable to effectively inhibit peritoneal implantation, especially miR-29b cannot be efficiently introduced into peritoneal mesothelial cells in vivo, resulting in poor treatment effects of peritoneal implantation.

Method used

An adeno-associated virus vector (AAV-miR-29b) carrying miR-29b was delivered to cells in the peritoneal cavity, inhibiting peritoneal implantation by expressing miR-29b.

Benefits of technology

It significantly inhibits the formation and progression of peritoneal implantation, provides a more effective peritoneal implantation inhibitor, can efficiently introduce miR-29b in vivo, and significantly reduce the number of peritoneal implantation nodules, especially the number of peritoneal implantation nodules on the mesentery.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120731090A_ABST
    Figure CN120731090A_ABST
Patent Text Reader

Abstract

The invention provides a peritoneal implantation inhibitor capable of effectively inhibiting peritoneal implantation. The peritoneal implantation inhibitor comprises an adeno-associated virus vector carrying miR-29b (micro Ribonucleic Acid-29b). The serotype of the adeno-associated virus vector comprises one of a group consisting of AAV1, AAV2, AAV4 and AAV-DJ. More specifically, for human (Homo sapiens), the serotype of the adeno-associated virus vector is AAV1, AAV2, AAV5, or AAV-DJ; for a mouse (Mus musculus), the serotype of the mouse is AAV1, AAV2, AAV5, AAV9 or AAV-DJ. By means of the peritoneal implantation inhibitor, cells forming the abdominal cavity can express miR-29b, and therefore peritoneal implantation can be treated or prevented.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention particularly relates to a peritoneal implantation inhibitor, a peritoneal implantation inhibitory method, a peritoneal implantation prevention method, and a peritoneal implantation treatment method. Background Art

[0002] Peritoneal dissemination is a form of metastasis and recurrence with a high frequency in cancers (malignant tumors) occurring in the abdominal cavity such as gastric cancer, pancreatic cancer, colorectal cancer, uterine cancer, and ovarian cancer. Peritoneal dissemination is the formation of countless small nodules in the abdominal cavity, which causes the accumulation of ascites and obstruction of the digestive tract, and may become a serious morbidity with a poor prognosis. However, in the past, there was no effective treatment for peritoneal dissemination, and there was no special treatment method targeting peritoneal dissemination. In addition, even if a radical operation visible to the naked eye can be performed, peritoneal dissemination often occurs a few months after the operation. Therefore, in cancers accompanied by peritoneal dissemination, the standard treatment method is chemotherapy by intravenously administering anticancer agents or molecular targeted drugs to the whole body. However, the transfer of these agents from the blood to the abdominal cavity is rare, and sufficient therapeutic effects are often not obtained. Therefore, a more effective treatment method is needed.

[0003] Here, referring to Patent Document 1, there has been a prior art description of a device carrying an attenuated herpes simplex virus effective in treating cancer and a composition for treating cancer containing the virus, wherein a foreign suicide gene is inserted into the attenuated herpes simplex virus.

[0004] The virus attacks the cancer cells that are associated with peritoneal implantation, but cannot prevent peritoneal implantation itself.

[0005] Thus, conventionally, there has been no reliable method for controlling peritoneal seeding. Therefore, establishing an effective method for preventing the recurrence of peritoneal seeding is considered to be the most important issue for improving the prognosis of cancer patients with peritoneal seeding of digestive organs and the like.

[0006] Here, with reference to Non-Patent Document 1, a study on the effects of miR-29b, a microRNA that is decreased in the peritoneal cavity of patients with peritoneal implantation of gastric cancer, is described.

[0007] According to non-patent literature 1, "miR-29b mimic", which is the RNA of miR-29b itself, was transfected into human peritoneal mesothelial cells (HPMC) by liposome transfection, and its effects were evaluated in vitro. When miR-29b was allowed to act on human peritoneal mesothelial cells stimulated by transforming growth factor β (Transforming Growth Factor-β, hereinafter referred to as "TGF-β"), proliferation was inhibited, and the migration ability and the adhesion ability of cancer cells to peritoneal mesothelial cells decreased significantly. Thus, miR-29b inhibited the mesothelial-mesenchymal transition (hereinafter referred to as "MMT") induced by TGF-β. Therefore, it is expected that it can inhibit peritoneal implantation. Therefore, when miR-29bmimic was complexed with atelocollagen and administered to a mouse peritoneal implantation model, peritoneal implantation in the omentum was suppressed but not in the mesentery.

[0008] Prior art literature

[0009] Patent Literature

[0010] Patent Document 1: Japanese Patent Application Laid-Open No. 2002-218975

[0011] Non-patent literature

[0012] Non-patent document 1: Kimura Y, Ohzawa H, Miyato H, et al., "MiR-29b may suppressesperitoneal metases through inhibition of the mesothelial-mesenchymaltransition (MMT) of human peritoneal mesothelial cells", Scientific Reports, 2022, 12(1): 205 Summary of the Invention

[0013] Problems to be solved by the invention

[0014] However, the technology of Non-Patent Document 1 (hereinafter referred to as "conventional technology"), using miR-29b, cannot actually achieve sufficient suppression of peritoneal implantation in vivo to be used as a therapeutic agent.

[0015] Therefore, there is a need for a peritoneal implantation inhibitor that can efficiently introduce miR-29b into peritoneal mesothelial cells and inhibit peritoneal implantation.

[0016] The present invention has been made in view of the above circumstances, and an object of the present invention is to solve the above problems.

[0017] Solutions to the Problem

[0018] The peritoneal seeding inhibitor of the present invention is characterized by comprising an adeno-associated virus vector carrying miR-29b.

[0019] The method for inhibiting peritoneal seeding of the present invention is characterized in that miR-29b is expressed in cells constituting the peritoneal cavity using an adeno-associated virus vector carrying miR-29b.

[0020] The method for preventing peritoneal seeding of the present invention is characterized in that miR-29b is expressed in cells constituting the peritoneal cavity using an adeno-associated virus vector carrying miR-29b.

[0021] The peritoneal implantation treatment method of the present invention is a peritoneal implantation treatment method for animals other than humans, characterized in that an adeno-associated virus vector carrying miR-29b is used to cause cells constituting the peritoneal cavity to express miR-29b.

[0022] Effects of the Invention

[0023] According to the present invention, since it contains an adeno-associated virus vector carrying miR-29b, miR-29b can be more effectively introduced into peritoneal mesothelial cells and the like than before, thereby providing a peritoneal seeding inhibitor that inhibits peritoneal seeding. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1A This is a conceptual diagram showing a carrier structure according to a first embodiment of the present invention.

[0025] Figure 1B This is a conceptual diagram showing a carrier structure according to a first embodiment of the present invention.

[0026] Figure 2 This is a photograph showing cultured human peritoneal mesothelial cells according to Example 1 of the present invention.

[0027] Figure 3A This is a conceptual diagram showing the results of a serum type selection experiment on human peritoneal mesothelial cells according to Example 1 of the present invention.

[0028] Figure 3B These are photographs showing the results of a serum type selection experiment on human peritoneal mesothelial cells according to Example 1 of the present invention.

[0029] Figure 3C This is a graph showing the results of a serum type selection experiment on human peritoneal mesothelial cells according to Example 1 of the present invention.

[0030] Figure 4A This is a conceptual diagram showing the results of a serum type selection experiment on mouse peritoneal mesothelial cells according to Example 1 of the present invention.

[0031] Figure 4B These are photographs showing the results of a serum type selection experiment on mouse peritoneal mesothelial cells according to Example 1 of the present invention.

[0032] Figure 4C This is a graph showing the results of a serum type selection experiment on mouse peritoneal mesothelial cells according to Example 1 of the present invention.

[0033] Figure 5 These are photographs showing the results of an experiment on the inhibition of mesothelial-mesenchymal transition by TGF-β according to Example 1 of the present invention.

[0034] Figure 6A This is a conceptual diagram showing the experimental results of introducing AAV into the mouse peritoneum according to Example 1 of the present invention.

[0035] Figure 6B These are photographs showing the experimental results of introducing AAV into the mouse peritoneum according to Example 1 of the present invention.

[0036] Figure 6C This is a graph showing the experimental results of introducing AAV into the mouse peritoneum according to Example 1 of the present invention.

[0037] Figure 7 This is a conceptual diagram showing a peritoneal implantation inhibition experiment (administration on the third day after cancer cell implantation) according to Example 1 of the present invention.

[0038] Figure 8A These are photographs showing the results of a peritoneal implantation inhibition experiment (administration on the third day after cancer cell implantation) according to Example 1 of the present invention.

[0039] Figure 8B This is a graph showing the results of a peritoneal implantation inhibition experiment (administration on the third day after cancer cell implantation) according to Example 1 of the present invention.

[0040] Figure 9 This is a conceptual diagram showing a peritoneal seeding inhibition experiment (simultaneous administration with cancer cell seeding) according to Example 1 of the present invention.

[0041] Figure 10A These are photographs showing the results of a peritoneal seeding inhibition experiment (administration simultaneously with cancer cell seeding) according to Example 1 of the present invention.

[0042] Figure 10B This is a graph showing the results of a peritoneal seeding inhibition experiment (administration simultaneously with cancer cell seeding) according to Example 1 of the present invention.

[0043] Figure 11A These are photographs showing changes in mouse peritoneum caused by AAV-DJ-miR-29b according to Example 1 of the present invention.

[0044] Figure 11B This is a graph showing changes in mouse peritoneum caused by AAV-DJ-miR-29b according to Example 1 of the present invention.

[0045] Figure 12A This is a conceptual diagram showing an experiment for suppressing peritoneal seeding of pancreatic cancer according to the second embodiment of the present invention.

[0046] Figure 12B These are photographs showing the results of an experiment on suppressing peritoneal seeding of pancreatic cancer according to Example 2 of the present invention.

[0047] Figure 12C This is a graph showing the results of an experiment on suppressing peritoneal seeding of pancreatic cancer according to Example 2 of the present invention.

[0048] Figure 12D These are photographs showing changes in the peritoneum of mice in an experiment to inhibit peritoneal seeding of pancreatic cancer according to Example 2 of the present invention.

[0049] Figure 12E This is a graph showing changes in the peritoneum of mice in the peritoneal seeding inhibition experiment for pancreatic cancer according to Example 2 of the present invention.

[0050] Figure 13A This is a conceptual diagram showing an experiment for inhibiting peritoneal seeding by combined use with an anticancer agent according to Example 2 of the present invention.

[0051] Figure 13B These are photographs showing the results of a peritoneal seeding inhibition experiment using an anticancer agent in combination with Example 2 of the present invention.

[0052] Figure 13C This is a graph showing the results of a peritoneal seeding inhibition experiment using anticancer drugs in combination according to Example 2 of the present invention. DETAILED DESCRIPTION

[0053] <Implementation Method>

[0054] Cancer, particularly gastric cancer, can metastasize through various pathways, including hematogenous metastasis, lymphatic metastasis, and implantation. It is believed that when gastric cancer originates from the mucosal surface of the stomach cavity and penetrates deep into the stomach, emerging from the serosal surface (i.e., the outer side), the cancer cells spread into the abdominal cavity and form peritoneal implants on the peritoneum.

[0055] Peritoneal seeding is a pathological condition that can easily lead to cancerous ascites and intestinal obstruction, and insufficient treatment is sometimes effective, a major clinical problem. Furthermore, for advanced cancers, adjuvant chemotherapy is performed after radical surgery, but peritoneal seeding can sometimes recur. However, there is no treatment to prevent peritoneal seeding in patients at high risk of recurrence, which is also a problem.

[0056] To this end, the present inventors comprehensively analyzed the exosomal miRNA in the ascites of gastric cancer patients with peritoneal implantation and the intraperitoneal washing fluid of early gastric cancer patients without peritoneal implantation, and found that miR-29 was significantly reduced in gastric cancer patients with peritoneal implantation.

[0057] The inventors discovered that among patients with gastric cancer that has spread deep into the serosa (T4), peritoneal implants show significantly reduced expression of miR-29b. They also confirmed that miR-29b is a tumor suppressor miRNA with anti-cancer effects. Therefore, the inventors speculated that targeting various cells within the peritoneal cavity could be a new treatment for peritoneal implants and conducted extensive research.

[0058] The inventors then examined miR-29b expression in various cell types using digital PCR and found that it was highly expressed in human peritoneal mesothelial cells (HPMCs). Since treatment of HPMCs with TGF-β decreases miR-29b expression, they hypothesized that the decrease in miR-29b in the peritoneal cavity may be due to decreased expression in peritoneal mesothelial cells.

[0059] The inventors therefore conceived of a therapeutic strategy to replenish miR-29b in the peritoneal cavity. Building on this foundation, while advancing their experiments with miR-29b, the inventors focused on the mesothelial-mesenchymal transition (MMT), a process in which peritoneal mesothelial cells transform into mesenchymal lineages and promote cancer progression, and investigated its mechanism of action. They found that reduced miR-29b expression was highly expressed in peritoneal mesothelial cells lining the peritoneal surface, but expression decreased in response to cancer cell stimulation. Furthermore, its expression was low in cancer cells and immune cells.

[0060] Therefore, as described in Non-Patent Document 1, miR-29b mimic, which is RNA itself, was transfected into peritoneal mesothelial cells stimulated with TGF-β using liposomes to enhance miR-29b expression. As a result, HPMC proliferation was inhibited, and the migration ability and adhesion of cancer cells to peritoneal mesothelial cells were significantly reduced. Furthermore, miR-29b inhibited the mesothelial-mesenchymal transition (MMT) induced by TGF-β.

[0061] Therefore, the inventors conducted further experiments using a syngeneic tumor transplant model to administer miR-29b locally. They mixed miR-29b with end-of-collagen and injected it into the peritoneal cavity of mice every three days. The number of peritoneal nodules in the greater omentum and mesentery was counted and evaluated. While peritoneal nodules in mice are typically evaluated based on the number of peritoneal nodules in the mesentery, this experiment showed no change in the number of peritoneal nodules in the mesentery. On the other hand, the number of peritoneal nodules in the greater omentum of mice was significantly reduced.

[0062] Unfortunately, however, miR-29b mimic continued to exert its effect on mesothelial-mesenchymal transition (MMT) and failed to achieve sufficient effect to be used as a therapeutic agent for peritoneal implantation.

[0063] Based on this, the inventors believed that it was necessary to efficiently deliver miR-29b to the peritoneal cavity and conducted further experiments. During this process, the inventors came up with the idea of ​​using an adeno-associated virus vector to deliver miR-29b to the peritoneal mesothelial cells that constitute the peritoneal cavity.

[0064] Then, the inventors actually prepared an adeno-associated virus vector carrying miR-29b, and repeatedly conducted in-depth experiments. Specifically, an adeno-associated virus serotype that is targeted to peritoneal mesothelial cells covering the surface of the abdominal cavity was selected, and the precursor sequence of miR-29b, whose expression was reduced in the peritoneal cavity of patients with peritoneal implantation, was inserted to prepare an adeno-associated virus vector "AAV-miR-29b" carrying miR-29b as described in Examples 1 and 2 below. The AAV-miR-29b was administered into the peritoneal cavity of a mouse peritoneal implantation model using the mouse gastric cancer cell line YTN16P. Then, compared with the control group, the peritoneal implant nodules on the mesentery were significantly reduced, and the effect of inhibiting the progression of peritoneal implantation was observed. In addition, when the cancer cell line and AAV-miR-29b were administered simultaneously, the number of peritoneal implant nodules was also significantly reduced, which had a preventive effect.

[0065] The results showed that the formation and progression of peritoneal implantation can actually be inhibited, and the present invention was finally completed.

[0066] While conventional cancer gene therapy is primarily developed by targeting cancer cells, the present invention modifies the amount of miR-29b in the host's peritoneal cavity, thereby controlling peritoneal seeding. Specifically, by using an adeno-associated viral vector to express miR-29b in cells within the host's peritoneal cavity, peritoneal seeding can be treated and prevented. Thus, the present invention provides effective therapeutic agents and methods for treating refractory cancer peritoneal seeding.

[0067] Hereinafter, embodiments of the present invention will be described in more detail.

[0068] [Peritoneal seeding inhibitor]

[0069] Specifically, the peritoneal seeding inhibitor according to the present embodiment is characterized in that it comprises an adeno-associated virus vector carrying miR-29b.

[0070] MicroRNA (also referred to as "miRNA" or "miR") is a type of functional RNA (non-coding RNA, ncRNA, or non-coding RNA) encoded in the genome. It undergoes a multi-step production process to become a single-stranded RNA molecule approximately 20 to 25 bases (nt) in length. MicroRNAs are involved in post-transcriptional gene expression regulation in eukaryotic organisms.

[0071] In this embodiment, as this microRNA, the precursor sequence of miR-29b with anticancer effect and reduced expression in the peritoneal cavity of peritoneal implant patients is introduced into a vector. An example of the sequence of miR-29b (transcribed into a microRNA state) shared by humans and mice used in this embodiment is shown in sequence number 1 of the sequence table.

[0072] However, the miR-29b involved in this embodiment is not necessarily a precursor sequence based on the DNA of miR-29b as shown in sequence number 1, but may also be a sequence identical to the miRNA gene on the genome, a precursor miRNA (pre-miRNA), a sequence based on mature miRNA (mature-miRNA), or a sequence that is ultimately synthesized into miR-29b after being activated by other intracellular processing.

[0073] In addition, it can also be a sequence that is modified to modify miR-29b, or enhance the inhibitory effect on mesothelial-mesenchymal transition (MMT) and amended. In addition, the sequence of the miR-29b can be a sequence of other animal species other than humans and mice, a sequence amended according to an animal species, etc., and the copy number, enhancer sequence, etc. carried on AAV can also be arbitrary. In addition, the miR-29b involved in this embodiment can also include other genes in sequence, such as other cancer suppressor miRNAs (Tumor Suppressor miRNA). Such other miRNAs with cancer suppressor effects, for example, can also be miR-34, etc.

[0074] On the other hand, adeno-associated virus (hereinafter also referred to as "AAV") belongs to the genus Dependinovirus of the family Parvoviridae that infects humans and primates. It is a small (about 20 nm) virus that relies on a helper virus and has no envelope.

[0075] In this embodiment, miR-29b is carried on AAV. AAV has the characteristics of low toxicity, low immunogenicity, and the ability to express continuously. In addition, AAV is actually a method that has been used in some clinical applications and has high safety. Therefore, in actual clinical applications, even carrying miR-29b can improve safety. In this embodiment, as described above, AAV carrying miR-29b is also referred to as "AAV-miR-29b."

[0076] Here, compared with the method of forming a complex of miR-29bmimic and terminal collagen and administering it in the above-mentioned non-patent document 1, the peritoneal implantation inhibitor using the AAV-miR-29b delivery method involved in this embodiment, as shown in Examples 1 and 2 described later, has an extremely high peritoneal implantation inhibitory effect in in vivo experiments using a mouse peritoneal implantation model, reaching a level that cannot be predicted by those skilled in the art, and shows a significant effect compared with the existing technology.

[0077] Furthermore, in the peritoneal seeding inhibitor according to the present embodiment, the serotype of AAV is characterized in that it includes one selected from the group consisting of AAV1, AAV2, AAV4, AAV5, AAV9, and AAV-DJ.

[0078] In particular, AAV2 is particularly suitable as the AAV serotype involved in this embodiment in humans (Homo sapiens), as shown in the results of selecting adeno-associated virus serotypes that target peritoneal mesothelial cells covering the peritoneal cavity surface in Examples 1 and 2 described below. Specifically, AAV2 has the highest targeting activity for peritoneal mesothelial cells. Furthermore, those skilled in the art have discovered that AAV2 also has inhibitory properties against cancer cells themselves. Therefore, a synergistic effect can be expected, making the use of this AAV2 vector particularly suitable.

[0079] On the other hand, in mice (Mus musculus), AAV1, AAV2, AAV4, AAV5, AAV9, or AAV-DJ are suitable. Among them, AAV-DJ is particularly suitable in mice.

[0080] Hereinafter, when it is necessary to distinguish whether AAV-miR-29b is carried on AAV of each serotype, it will be described as AAV2-miR-29b, AAV-DJ-miR-29b, etc.

[0081] Specifically, the peritoneal seeding inhibitor of this embodiment is characterized by causing cells within the peritoneal cavity to express miR-29b, thereby treating or preventing peritoneal seeding. Specifically, by using AAV to deliver miR-29b to cells within the peritoneal cavity and causing their expression, the formation and progression of peritoneal seeding can be inhibited or prevented.

[0082] The cells constituting the abdominal cavity targeted by the peritoneal implantation inhibitor involved in this embodiment can be, for example, various cells constituting the membranous tissue covering the surface of body cavities such as the abdominal cavity, thoracic cavity, and pericardium. Among them, in this embodiment, in particular, as the cells constituting the abdominal cavity, peritoneal mesothelial cells constituting the peritoneal mesothelium are described as the main target cells, but other cells can also be used. That is, the cells constituting the abdominal cavity involved in this embodiment can be various cells constituting the membranous tissue that undergo fibrosis and cancer cells are easily metastatic when miR-29b is reduced (hereinafter, these cells are referred to as "peritoneal mesothelial cells, etc.").

[0083] Furthermore, the peritoneal seeding inhibitor according to this embodiment is characterized by inhibiting mesothelial-mesenchymal transition (MMT) in cells that constitute the peritoneal cavity, thereby suppressing peritoneal fibrosis. Specifically, the peritoneal seeding inhibitor according to this embodiment inhibits mesothelial-mesenchymal transition (MMT) that occurs in peritoneal mesothelial cells and the like due to stimulation by cancer cells, inflammatory substances, and the like. This significantly inhibits the migratory ability of peritoneal mesothelial cells and the like, thereby suppressing peritoneal fibrosis throughout the peritoneum.

[0084] Therefore, the peritoneal seeding inhibitor according to this embodiment can reduce the adhesion ability of cancer cells to peritoneal mesothelial cells and the like, and can treat or prevent peritoneal seeding.

[0085] Furthermore, cancers targeted by the peritoneal seeding inhibitor according to the embodiment of the present invention include gastric cancer, pancreatic cancer, colorectal cancer, uterine cancer, ovarian cancer, and the like that occur in the abdominal cavity.

[0086] Furthermore, the peritoneal seeding inhibitors according to embodiments of the present invention can also be applied to other cancers that may develop peritoneal seeding. For example, the therapeutic agents according to this embodiment can be applied to peritoneal seeding caused by various cancers, including head and neck cancer, esophageal cancer, liver cancer, gallbladder cancer, lung cancer, kidney cancer, testicular cancer, breast cancer, prostate cancer, bladder cancer, skin cancer, thyroid cancer, malignant lymphoma, and other sarcomas. In other words, the peritoneal seeding inhibitors according to this embodiment can inhibit the development of peritoneal seeding caused by the invasion and metastasis of these peritoneal seedings.

[0087] In order to perform such treatment or prevention, the peritoneal seeding inhibitor according to the present embodiment is preferably administered concurrently with or after tumor surgery.

[0088] As shown in Example 1 below, the peritoneal seeding inhibitor of this embodiment can suppress the number of peritoneal seeding nodules, whether administered three days after cancer cell seeding or simultaneously with cancer cell seeding. Furthermore, as shown in Example 2 below, even after peritoneal seeding has already occurred, intraperitoneal administration along with an anticancer agent can suppress the number of peritoneal seeding nodules.

[0089] Therefore, as a means of preventing peritoneal seeding at an extremely early stage, administration can be performed in a situation where "peritoneal seeding is not observed at the time of surgery, but a very small amount of cancer cells remain that are difficult to detect through conventional examinations." For example, administration can be performed in a situation where the patient has T4 gastric cancer and CY0 (negative diagnosis of intraperitoneal lavage cells). In other words, in this situation, by administering the peritoneal seeding inhibitor of this embodiment, it is expected that the formation and progression of peritoneal seeding can be suppressed.

[0090] Alternatively, the peritoneal seeding inhibitor according to this embodiment can be administered during surgery. Specifically, the present inventors have found that among T4 gastric cancer patients with low miR-29b levels, peritoneal seeding is more likely to occur. Therefore, administering the peritoneal seeding inhibitor according to this embodiment during surgery can prevent the occurrence and recurrence of peritoneal seeding after surgery.

[0091] In this case, the peritoneal implantation inhibitor according to the present embodiment can be directly administered into the abdominal cavity during or after the above-mentioned surgery.

[0092] With this configuration, as shown in Examples 1 and 2 below, the peritoneal seeding inhibitor of this embodiment can help inhibit or prevent the formation and progression of peritoneal seeding caused by mesothelial-mesenchymal transition. That is, as in Examples 1 and 2, AAV is injected into the peritoneal cavity. The peritoneal seeding inhibitor of this embodiment can be directly administered into the peritoneal cavity using methods commonly used by those skilled in the art, such as injection, infusion, or intraoperative spraying.

[0093] Thus, the peritoneal seeding inhibitor according to this embodiment can be used as a drug such as a therapeutic agent (therapeutic composition) or a preventive agent (preventive composition) for peritoneal seeding. Specifically, the peritoneal seeding inhibitor according to this embodiment can be used as a drug to inhibit peritoneal seeding and prevent recurrence of surgically treatable cancers caused by peritoneal seeding.

[0094] In fact, as shown in Examples 1 and 2 below, the use of miR-29b can inhibit mesothelial-mesenchymal transition, thereby suppressing the formation and progression of peritoneal implants. Therefore, miR-29b can be used as a therapeutic agent for peritoneal implants.

[0095] Furthermore, as described above, in the present embodiment, miR-29b is expressed in cells constituting the peritoneal cavity using AAV carrying miR-29b, and this can be used as a method for suppressing peritoneal seeding and a method for preventing peritoneal seeding.

[0096] With this configuration, the peritoneal seeding inhibitor of this embodiment can be used as a therapeutic agent or a treatment method to inhibit or prevent the formation and progression of peritoneal seeding caused by mesothelial-mesenchymal transition, and can also inhibit the proliferation of peritoneal seeding that carries a poor prognosis. In other words, the therapeutic agent of this embodiment can be provided as a treatment for peritoneal seeding caused by cancer metastasis occurring in the abdominal cavity by preventing peritoneal fibrosis.

[0097] Furthermore, the peritoneal seeding inhibitor according to this embodiment can also be used in combination with drugs used in standard clinical cancer treatment methods.

[0098] That is, the peritoneal seeding inhibitor according to this embodiment can be used in combination with an anticancer drug.

[0099] Specifically, it can be used in combination with anticancer agents used for chemotherapy by those skilled in the art. That is, by using the peritoneal seeding inhibitor according to this embodiment in combination with an anticancer agent used to treat peritoneal seeding, the formation and progression of peritoneal seeding can be more effectively inhibited or prevented than using the anticancer agent alone.

[0100] Furthermore, the peritoneal seeding inhibitors according to this embodiment may include, in addition to miR-29b itself, a synthesis promoter or degradation inhibitor of miR-29. Specifically, the peritoneal seeding inhibitors according to this embodiment use the biosynthesis system of miR-29b as a therapeutic target for peritoneal seeding of cancers occurring in the peritoneal cavity, and include substances that promote the synthesis of miR-29b, i.e., synthesis promoters, and substances that inhibit the degradation of miR-29b, i.e., degradation inhibitors.

[0101] Specifically, the miR-29b synthesis promoter or degradation inhibitor can be a miR-29b gene expression regulator. Specifically, various gene regulators targeting pathways related to the synthesis and degradation of miR-29b can be used as gene expression regulators.

[0102] The gene regulator can be, for example, a regulatory nucleic acid (nucleotide), such as DNA or RNA, that performs transcription and modification in the biosynthetic pathway of the miR-29b gene, or it can be a peptide containing antibodies, peptide nucleic acid (PNA), nucleic acid or protein involved in genome editing, etc., targeting various enzymes and other proteins (hereinafter referred to as "target proteins").

[0103] The nucleic acid may be antisense DNA or RNA, small interfering RNA (siRNA), short hairpin RNA (shRNA), ribozyme, or the like.

[0104] Furthermore, the gene expression regulator of this embodiment can be identified based on the amino acid sequence, mRNA sequence, genomic DNA sequence, etc. of the target protein, and can be prepared by methods that can be easily performed by those skilled in the art.

[0105] Thus, various compositions targeting the biosynthetic pathways involved in the synthesis and degradation of miR-29b, including miR-29b synthesis promoters or degradation inhibitors, can also be provided as therapeutic agents for peritoneal implantation. In other words, these compositions can be provided as peritoneal implantation inhibitors that inhibit the formation and progression of peritoneal implantation.

[0106] In addition, as the peritoneal seeding inhibitor of the present embodiment, a synthesis promoter or degradation inhibitor targeting the same pathway as that regulating the gene expression of miR-29b can also be used.

[0107] In addition, various medical compositions such as low molecular weight compounds, antibody drugs, nucleic acids, and peptide nucleic acids (PNA) that target enzymes involved in mesothelial-mesenchymal transition (MMT) can be used as peritoneal seeding inhibitors of this embodiment. For example, low molecular weight compounds can be synthesized and used in combination as peritoneal seeding inhibitors.

[0108] Furthermore, the peritoneal seeding inhibitor of this embodiment can be incorporated into medical compositions that promote apoptosis of cancer cells, stimulate the cancer immune system, or implement techniques related to genetic modification such as genome editing.

[0109] Furthermore, when the peritoneal implantation inhibitor according to the embodiment of the present invention is a low molecular weight compound, it can be provided in the form of various salts. These salts can be prepared by reacting the low molecular weight compound with an acid or base that can be used in the production of pharmaceuticals.

[0110] In addition, as the peritoneal seeding inhibitor involved in this embodiment, for inoperable peritoneal seeding, that is, cases with highly advanced disease, it may be difficult to inhibit disease progression by simply strengthening the peritoneal mesothelium with miR-29b. Therefore, AAV vectors expressing anti-miRNA or miRNA inhibitors can be administered simultaneously.

[0111] Furthermore, the peritoneal seeding inhibitor according to this embodiment may be used in combination with other regulators that can inhibit mesothelial-mesenchymal transition of cells constituting the peritoneal cavity.

[0112] Furthermore, the therapeutic agent of this embodiment can enhance the therapeutic effect by combining it with various tumor adhesion inhibitors, tumor angiogenesis inhibitors, and the like to inhibit the adhesion of cancer cells and angiogenesis from implanting into the peritoneum.

[0113] In addition, various medical vectors other than AAV can be added to AAV for use. Examples of such viral vectors include adenoviral vectors, lentiviral vectors, and retroviral vectors. Using vectors that can retain DNA longer than AAV makes it possible to achieve specific genome editing of tumors, such as primary lesions of cancer implanted in the peritoneum, as the target of treatment.

[0114] Furthermore, the peritoneal seeding inhibitors according to embodiments of the present invention also include prodrugs. Here, a prodrug refers to a derivative that, after administration, is decomposed and converted under physiological conditions, such as specific pH conditions or the action of enzymes. Furthermore, a prodrug may be inactive when administered to a patient, but is converted into an active therapeutic agent in vivo.

[0115] In addition, the peritoneal seeding inhibitor according to the embodiment of the present invention may contain, as an acceptable carrier for any formulation, for example, physiological saline, unterminated collagen, other collagens, etc. Furthermore, it may be administered together with glucose, D-sorbitol, D-mannose, D-mannitol, ethanol, polyols (such as propylene glycol, polyethylene glycol), nonionic surfactants, etc. as a carrier.

[0116] Furthermore, the peritoneal seeding inhibitor according to the embodiment of the present invention may contain a suitable pharmaceutically acceptable carrier in order to prepare a pharmaceutically acceptable carrier, such as a biocompatible material such as silicone, collagen, or gelatin.

[0117] In addition, the pharmaceutical composition may contain additives such as diluents, flavorings, preservatives, excipients, disintegrants, lubricants, binders, emulsifiers, plasticizers, etc. Furthermore, the therapeutic agent of this embodiment may contain appropriate excipients and the like.

[0118] Furthermore, the peritoneal seeding inhibitor according to the embodiment of the present invention can be formulated in a form suitable for administration using pharmaceutically acceptable carriers known in the art.

[0119] [Treatment methods for peritoneal implantation]

[0120] Furthermore, the therapeutic method according to an embodiment of the present invention is a therapeutic method for peritoneal seeding, characterized by administering the aforementioned peritoneal seeding inhibitor.

[0121] Specifically, the peritoneal implant treatment method according to this embodiment is a method for treating peritoneal implants in animals, characterized by using an adeno-associated virus vector carrying miR-29b to cause cells within the peritoneal cavity to express miR-29b. Specifically, miR-29 can be expressed in cells within the peritoneum and used to treat peritoneal implants in animals that develop peritoneal implants.

[0122] Furthermore, the therapeutic agent according to the embodiment of the present invention can be used to treat a living organism or a part of a living organism. The living organism is not particularly limited and includes, for example, humans, domestic animals, wild animals, and other animals.

[0123] In this case, the therapeutic agents according to the embodiments of the present invention can be used as therapeutic targets mainly in humans and various vertebrates other than humans.

[0124] The non-human animals are not particularly limited and include various mammals, including placental mammals of the subclass Eutheria. Specifically, examples include rodents such as mice, rats, ferrets, hamsters, guinea pigs, and rabbits; dogs, cats, sheep, pigs, cattle, horses; and non-human transgenic primates. In other words, the peritoneal seeding treatment agents according to the embodiments of the present invention can be used not only for the treatment of humans but also for methods of inhibiting or preventing peritoneal seeding in various animals.

[0125] Furthermore, in countries where human treatment is industrially applicable (and can become a patent requirement), the scope of application of the treatment method according to the embodiment of the present invention may also include humans.

[0126] The administration route of the pharmaceutical composition according to the embodiment of the present invention is not particularly limited, and the composition can be administered by parenteral administration or oral administration.

[0127] In addition to the above-mentioned intraperitoneal injection together with a vector and peritoneal spraying during surgery, parenteral administration includes intravenous, intraarterial, subcutaneous, intradermal, and intramuscular administration.

[0128] Furthermore, in order to use the therapeutic agent according to the embodiment of the present invention for the above-mentioned treatment, the dosing interval and dosage can be appropriately selected and changed according to various conditions such as the state of the tumor and the condition of the subject.

[0129] Here, when treating, a dosage that can slow down tumor growth can be used. In addition, when used in combination with other therapeutic agents, nausea and severe side effects can be suppressed, thereby being effectively used.

[0130] The dosage and frequency of administration of the therapeutic agents according to the embodiments of the present invention to cancer patients with potential peritoneal implantation can be appropriately selected and modified according to the purpose of administration and various conditions such as the patient's age, weight, symptoms, and severity of the disease.

[0131] The frequency and duration of administration require monitoring of the patient's condition, and administration should be repeated or repeated according to the condition.

[0132] The therapeutic agent involved in the embodiment of the present invention is characterized in that it is used in combination with an anticancer agent. That is, the therapeutic agent involved in the embodiment of the present invention can be used in combination with other therapeutic compositions such as traditional chemotherapy agents and anticancer agents. The anticancer agent here, for example, can be included in the drugs used for peritoneal implantation treatment by those skilled in the art such as paclitaxel shown in the second embodiment described later, other types of drugs can also be used, and a combination of multiple therapeutic compositions (cocktail therapy) can also be used. Thus, it can be expected to obtain the treatment and prevention effects of peritoneal implantation. Moreover, even in the case where treatment has already begun, the therapeutic agent involved in this embodiment can also be used.

[0133] Furthermore, it can be used in combination with other cancer therapeutic agents or treatment methods such as radiotherapy, particle beam therapy, and surgery, thereby potentially becoming an effective treatment for peritoneal implants with a poor prognosis.

[0134] In addition to the therapeutic agent of the present embodiment, a therapeutic composition that can relieve pain and improve quality of life (QOL) can also be added for treatment. In addition, the composition of the present invention can be administered simultaneously with other compositions or at intervals of a certain period of time, and there is no particular limitation on the order of administration.

[0135] Furthermore, in the embodiments of the present invention, the period during which the disease is improved or alleviated is not particularly limited, and the improvement or alleviation may be temporary or last for a certain period of time.

[0136] [Effects of the Invention]

[0137] The traditional treatment for peritoneal implants is only chemotherapy, and no effective therapeutic drugs or treatments targeting peritoneal implants have been developed.

[0138] In contrast, using the peritoneal seeding inhibitor of this embodiment, as shown in Example 1 below, when AAV-miR-29b was intraperitoneally administered to a mouse peritoneal seeding model using the mouse gastric cancer cell line YTN16P, the number of peritoneal seeding nodules in the mesentery was significantly reduced compared to the control group, demonstrating an inhibitory effect on the progression of peritoneal seeding. Furthermore, as shown in Example 2 below, in other highly malignant cancers such as pancreatic cancer, the number of peritoneal seeding nodules in the mesentery was also significantly reduced compared to the control group, demonstrating an inhibitory effect on the progression of peritoneal seeding. In other words, the progression of peritoneal seeding can be inhibited in pancreatic cancer, a cancer with a prognosis comparable to or worse than that of gastric cancer.

[0139] In summary, the peritoneal seeding inhibitor of this embodiment can act on peritoneal mesothelial cells rather than cancer cells, thereby effectively inhibiting tumor formation.

[0140] Furthermore, when cancer cell lines and AAV-miR-29b were administered simultaneously, the number of peritoneal nodules was significantly reduced, suggesting a preventive effect. These results suggest that a single intraperitoneal administration of AAV-miR29b at the end of surgery for patients with T4CYO gastric cancer who have a high degree of wall penetration (T4) and a negative wash cytology diagnosis (CYO) may be able to prevent future recurrences of peritoneal nodules. This suggests that treatment can be targeted at preventing peritoneal nodules, a difficult-to-treat condition.

[0141] Specifically, as therapeutic effect and preventive effect, the metastatic lesions of the cancer of peritoneal implantation can be suppressed to cover the peritoneum or to proliferate as a nodule, and then block the digestive tract and other organs, tissues. In addition, it is expected to improve cachexia, and prevent the generation of new peritoneal implantation. And, by chemotherapy, anticancer agent or surgical removal, extraction or excision of each metastatic lesion, it is also possible to expect that cancer itself is alleviated. In fact, as shown in aftermentioned embodiment two, with chemotherapy (anticancer agent) and use, the progress of peritoneal implantation can be further suppressed.

[0142] [Other Implementation Methods]

[0143] In addition, the viral vector involved in other embodiments of the present invention and the peritoneal implantation inhibition method involved in other embodiments of the present invention are characterized in that the expression level of miR-29b in the collected intraperitoneal fluid can be measured to predict the prognosis.

[0144] With this configuration, measuring the expression of miR-29b in peritoneal cell samples collected during surgery or examinations can determine the susceptibility of peritoneal implantation (predicting prognosis) and the effectiveness of treatment. In other words, miR-29b and other markers measured in the peritoneum can be used as markers to predict prognosis and treatment effectiveness.

[0145] Specifically, by measuring the expression of miR-29b and other proteins in peritoneal cells obtained during cancer surgery using various methods such as RT-PCR, digital PCR, and Northern blot, it is possible to assess the susceptibility of peritoneal seeding and determine the prognosis. Thus, by measuring the expression of miR-29b and other proteins, it is possible to predict the likelihood of tumor metastasis due to peritoneal seeding and the prognosis, thereby providing a diagnostic method that can be used to select treatments. The expression level here can be absolute, relative, or a concentration based on a "level" within a specific expression range.

[0146] This structure, combined with a prognostic prediction method, allows for effective treatment after investigating the susceptibility of peritoneal implantation. Furthermore, after drug administration, the expression levels of miR-29b and other proteins in the peritoneum can be used as a reference to determine the effectiveness of treatment.

[0147] In addition, in this embodiment, the term "one or more" refers to any one of one or more combinations of each configuration. That is, any one of these may be used, or any combination of two to all of these may be used.

[0148] [Example 1]

[0149] The present invention will be further described below by way of examples based on the accompanying drawings, but the following specific examples do not limit the present invention.

[0150] [Experimental Method]

[0151] (Construction of plasmid DNA)

[0152] pAAV-CMV-MCS (manufactured by Takara Biotech Co., Ltd.) was cut with restriction endonucleases BamHI and XbaI, and the precursor sequence of miR-29b (hereinafter referred to as "mir-29b-1 sequence", which is shown in sequence number 1) obtained from pLV-[hsa-mir-29b-1] (manufactured by Biosettia) expressing miR-29b cut with BamHI and XbaI was introduced to prepare pAAV-CMV-[mir-29b-1].

[0153] Figure 1A The structure of pAAV2-CMV-MCS is shown. Figure 1B The structure of the prepared pAAV-CMV-[mir-29b-1] vector is shown.

[0154] (AAV Vector Recovery) HEK293 (human embryonic kidney) cells were cultured and transfected with pAAV-CMV-[mir-29b-1], AAV plasmids encoding AAV serotypes 1 to 10 and AAV-DJ, and helper plasmids (manufactured by Takara Biotech Co., Ltd.) using the calcium phosphate method. After 72 hours, the HEK293 cells were stripped and recovered, disrupted to release the AAV vector, and treated with an endonuclease. The supernatant was then centrifuged and recovered.

[0155] The recovered AAV vector solution is mixed with cesium chloride and processed by density gradient ultracentrifugation to recover the fraction containing the AAV vector. After dialysis against vector buffer, PCR quantification is performed to determine the vector concentration in the sample.

[0156] (Isolation of Peritoneal Mesothelial Cells)

[0157] Human peritoneal mesothelial cells were isolated and cultured with the approval of the Jichi Medical University Ethics Review Committee and after explanation and consent from the patient. 2-4 cm peritoneal mesothelial cells were obtained during non-cancer surgery (obesity surgery) from patients. 3The omentum tissue was immediately immersed in TrypLE Express (Thermo Fisher Scientific) diluted to half concentration with phosphate-buffered saline (PBS) and incubated at 37°C for 2 hours. The supernatant was filtered through a 100 μm nylon mesh filter and centrifuged at 1500 rpm at 4°C for 5 minutes. The recovered cells were resuspended in DMEM medium (Cosmo Bio Inc.) containing 20% ​​FBS (Fetal Bovine Serum, Sigma), 100 U / ml penicillin, and 100 mg / ml streptomycin, and cultured in a 37°C, 5% CO2 incubator.

[0158] Figure 2 Shown are the conditions of cultured human peritoneal mesothelial cells.

[0159] For mice, C57BL / 6N mice (manufactured by Clair Japan Co., Ltd.) were sacrificed and the greater omentum was collected. Peritoneal mesothelial cells were isolated and cultured using the same method as for humans.

[0160] 〔result〕

[0161] (Serotype selection experiment for peritoneal mesothelial cells and gastric cancer cell lines)

[0162] First, human or mouse peritoneal mesothelial cells were infected with a control vector expressing GFP to investigate the targeting of AAV serotypes to peritoneal mesothelial cells.

[0163] For this purpose, control AAV vectors were prepared in which the GFP gene was inserted as a reporter gene into AAV serotypes AAV1 to 10 and AAV-DJ. These vectors are hereinafter referred to as AAV1 to 10 and AAV-DJ vectors, respectively.

[0164] In a 24-well plate, 1 × 10 4 Human and mouse peritoneal mesothelial cells and mouse gastric cancer cell line YTN16P (provided by Dr. S. Nomura, University of Tokyo). After culturing overnight, 1×10 5 vg (vector genome), human peritoneal mesothelial cells were observed using a fluorescence microscope 3 days after incubation, and mouse peritoneal mesothelial cells were observed 7 days after incubation, and the proportion of GFP-expressing cells was measured by flow cytometry.

[0165] Figure 3A to Figure 3C Shown are the results of a serotype selection experiment in which human peritoneal mesothelial cells were infected with a control vector expressing GFP. Figure 3A This is a conceptual diagram of the experiment. Figure 3BThese are photographs showing GFP expression by each vector. Figure 3C It is a graph showing the median fluorescence intensity (MFI) of GFP expression obtained by flow cytometry.

[0166] The results showed that AAV2 vectors have the highest targeting efficiency. In other words, serotype 2 has the highest delivery efficiency in humans. AAV1, AAV5, and AAV-DJ also have targeting properties and can be used.

[0167] Figures 4A to 4C The results of the same serotype selection experiment on mouse peritoneal mesothelial cells are shown.

[0168] Figure 4A This is a conceptual diagram of the experiment. Figure 4B These are photos of GFP expression in each vector. Figure 4C It is a graph showing the MFI of GFP expression.

[0169] The results showed that the AAV-DJ vector had the highest targeting efficiency for the peritoneal mesothelium in mice. This means that the DJ serotype had the highest delivery efficiency in mice. In addition, AAV1, AAV2, AAV4, AAV5, and AAV9 also have targeting efficacy in mice and can be used.

[0170] The inventors also conducted similar experiments on the mouse gastric cancer cell line YTN16P and confirmed that GFP expression was weak regardless of serotype. This suggests that AAV is difficult to introduce into mouse gastric cancer cell lines, regardless of serotype.

[0171] (TGF-β-based inhibition of mesothelial-mesenchymal transition in peritoneal mesothelial cells)

[0172] Next, we verified whether AAV2-miR-29b could inhibit the transformation of peritoneal mesothelial cells into mesenchymal cells through transforming growth factor-β (TGF-β).

[0173] In this experiment, 1 × 10 4 Human peritoneal mesothelial cells were cultured and TGF-β (manufactured by Proteintech Japan Co., Ltd.) was added at a concentration of 10 ng / ml. The next day, 1×10 5 vg (vector genome) AAV2-miR-29b vector was injected into the ovary, and immunofluorescence staining was performed 3 days later. The expression of epithelial and mesenchymal cell markers was observed under a fluorescence microscope.

[0174] Figure 5 The results are shown. "NoTreat" represents a control group to which no substance was added, "TGF-β" represents a control group to which only TGF-β was added, "TGF-β1+AAV2-miR-29b" represents a group to which the AAV2-miR-29b vector of this embodiment was added, and "TGF-β1+AAV2-NC" represents the result of the pAAV2 negative control vector. The pAAV2 negative control vector is an AAV vector prepared from a plasmid DNA vector that does not contain the miR-29b precursor sequence. In each column, "Bright Field" is a microscope photograph, and "E-cadherin", "Calretinin", "Vimentin", "Fibronectin", and "DAPI" represent epithelial and mesenchymal cell markers, respectively. Regarding Fibronectin, in Non-Patent Literature 1, it is added for confirmation as one of the mechanisms of reducing cancer cell adhesion based on miR-29b, which is a mechanism through Fibronectin and integrin.

[0175] The results showed that miR-29b can inhibit the increase in expression of vimentin, a mesenchymal lineage marker, induced by TGF-β. This indicates that even when TGF-β is added to peritoneal mesothelial cells, the AAV2-miR-29b vector can inhibit the mesothelial-mesenchymal transition.

[0176] (Experiment on AAV transfection into mouse peritoneum)

[0177] Here, since the results of the above-mentioned in vitro experiments using human peritoneal mesothelial cells showed inhibition of mesothelial-mesenchymal transition, it was decided to conduct in vivo experiments using mice.

[0178] First, the AAV-DJ-miR-29b vector, which has the highest transfer efficiency in mice, was introduced to confirm that miR-29b was actually expressed in the peritoneum.

[0179] In this experiment, 8-week-old C57BL / 6N mice were injected intraperitoneally with 5 × 10 10 vg of AAV-DJ-miR-29b and AAV-DJ-GFP as a control vector, and the mice were sacrificed on day 28. In the group administered with AAV-DJ-GFP, GFP expression in peritoneal mesothelial cells was observed by fluorescence microscopy. In addition, in the group administered with AAV-DJ-miR-29b, miR-29b expression in peritoneal mesothelial cells was detected using cells obtained from the greater omentum of mice (the culture source of peritoneal mesothelial cells) using the same digital PCR method (kit manufactured by Thermo Fisher Scientific) as in Non-Patent Document 1.

[0180] Figure 6A is a conceptual diagram showing the experiment.

[0181] Figure 6B The figure shows the amount of GFP expressed in the peritoneum by AAV-DJ-GFP. After 28 days, the no-treatment group (no treatment) showed no GFP expression, while the control vector-treated group (AAV-DJ-GFP group) showed GFP expression. This demonstrates that DJ serotype AAV can reliably enter the peritoneum of mice.

[0182] Figure 6C The figure shows the expression level of miR-29b (copies / μL) in mouse peritoneal mesothelial cells (MPMCs) obtained from the peritoneum. One-way ANOVA analysis revealed that miR-29b expression was significantly increased in the AAV-DJ-miR-29b-treated group (AAV-DJ-miR-29b) compared to the no-treat control group and the negative control group (AAV-DJ-NC) administered with the AAV-DJ vector alone (p < 0.01).

[0183] (AAV-DJ-miR-29b inhibition experiment on peritoneal implantation)

[0184] Next, we actually investigated in vivo whether AAV-DJ-miR-29b could inhibit peritoneal seeding by changing the administration time to day 3 or administering simultaneously.

[0185] according to Figure 7 First, the outline of the peritoneal implantation inhibition experiment (administered on the 3rd day after cancer cell implantation) is described. Here, it is assumed that cancer cells are administered into the peritoneal cavity in order to prevent peritoneal implantation at the very early stage of formation. Three days later, AAV-DJ-miR-29b is diluted with phosphate buffered saline (PBS) and injected into the peritoneal cavity. The number of peritoneal implantation nodules on the greater omentum and mesentery is then counted and evaluated. Specifically, 1×10 5 Three days later, 5×10 5 vg of AAV-DJ-miR-29b and AAV-DJ-GFP, and the mice were sacrificed 3 weeks later. The number of peritoneal implants in the mesentery and omentum was measured for the following three groups: (1) a control group without AAV vector administration (No treat), (2) a group administered with AAV-DJ-miR-29b (AAV-DJ-miR-29b), and (3) a negative control group administered with AAV-DJ vector alone (AAV-DJ-NC), with n = 5 per group.

[0186] Figure 8A These are photographs showing the mesentery of each group in the peritoneal seeding inhibition experiment (administered 3 days after cancer cell seeding).

[0187] Figure 8B Comparison of the number of nodules in each group showed that the number of peritoneal implanted nodules on the mesentery was significantly reduced in the group administered with AAV-DJ-miR-29b (p < 0.05).

[0188] Specifically, after intraperitoneal administration of AAV-miR-29b in a mouse peritoneal implantation model, the number of peritoneal implantation nodules on the mesentery was significantly reduced compared to the control group, and an effect of inhibiting the progression of peritoneal implantation was observed.

[0189] according to Figure 9 , the outline of the peritoneal implantation inhibition experiment (administered simultaneously with cancer cell implantation) is described. Here, it is assumed that preventive administration is performed during surgery, and AAV-DJ-miR-29b is administered simultaneously with cancer cells into the peritoneal cavity, and then the number of peritoneal implantation nodules is counted and evaluated. Specifically, as in the experimental example in Figure 8 above, 1×10 5 Mouse gastric cancer cell line YTN16P2 was injected intraperitoneally with 5×10 5 vg were injected with AAV-DJ-miR-29b and AAV-DJ-GFP, and the mice were sacrificed 3 weeks later to measure the number of peritoneal implant nodules in the mesentery and omentum.

[0190] Figure 10A Shown are photographs of the mesentery of each group in the peritoneal seeding inhibition experiment (administered simultaneously with cancer cell seeding).

[0191] Figure 10B The number of nodules in each group was compared. In the group administered with AAV-DJ-miR-29b, the number of peritoneal implanted nodules on the mesentery was significantly reduced (p < 0.05).

[0192] That is, even when cancer cell lines and AAV-miR-29b were administered simultaneously, the number of peritoneal nodules was significantly reduced, suggesting a preventive effect.

[0193] (AAV-DJ-miR-29b affects the peritoneum of mice)

[0194] Next, the inhibitory effect of AAV-DJ-miR-29b on peritoneal fibrosis in mice was confirmed.

[0195] Specifically, frozen sections of mouse peritoneal tissue collected during the peritoneal seeding inhibition experiment were observed using a fluorescence microscope. Furthermore, Masson's trichrome staining was performed using a Trichrome Stain Kit (manufactured by ScyTek Laboratories) to detect collagen connective tissue fibers in the tissue sections, and peritoneal thickness was measured.

[0196] Figure 11A are photographs showing changes that occurred in the peritoneum of mice in this experiment.

[0197] Figure 11B The results of the comparison of peritoneal thickness between the groups showed that no peritoneal thickening was observed in the group administered with AAV-DJ-miR-29b. In other words, peritoneal fibrosis was significantly suppressed (p<0.05) in the AAV-miR-29b group.

[0198] [Example 2]

[0199] (Effect on pancreatic cancer)

[0200] In the above-mentioned Example 1, the effect on the mouse gastric cancer peritoneal implantation model was demonstrated, and therefore, the effect on other epithelial malignancies (carcinoma) was also confirmed.

[0201] In this example, the pancreatic cancer peritoneal implantation model established with mouse pancreatic cancer cells PAN02 was used to confirm the inhibitory effect on pancreatic cancer peritoneal implantation.

[0202] Figure 12A is a conceptual diagram showing the experiment.

[0203] In this experiment, 5×10 5 PAN02 mouse pancreatic cancer cells, and 5×10 10 vg (vector genome) of AAV-DJ-miR-29b.

[0204] Mice were sacrificed on day 14, and peritoneal implantation was assessed by counting the number of peritoneal implant nodules in the mesentery. Because the pancreatic and gastric cancer cell lines used in the experiment exhibit different peritoneal implantation patterns, the pancreatic cancer model was evaluated after day 14.

[0205] The parietal peritoneum was fixed with 4% formalin and then embedded in paraffin. The sections were cut into 4 μm thick sections and stained with Masson's trichrome. The thickness of the abdominal wall was measured.

[0206] Figure 12BPhotos of pancreatic cancer mesentery in each group are shown. "Notreatment" indicates the group administered with cancer cells alone. "AAV-DJ-NC" indicates the negative control group administered with only the AAV-DJ vector. "AAV-DJ-miR-29b" indicates the group administered with the AAV-DJ-miR-29b of this example.

[0207] Figure 12C The figures show the results of measuring the number of mesenteric implant nodules when pancreatic cancer cells and AAV-miR-29b were co-administered and peritoneal implant formation was assessed on day 14.

[0208] In the AAV-miR29b-administered group, the number of peritoneal implants in the mesentery was significantly suppressed. "***" in the figure indicates p < 0.01.

[0209] Figure 12D Similar to the gastric cancer model in Example 1, these are photos showing changes in the peritoneum in frozen sections of peritoneal tissue observed using a fluorescence microscope.

[0210] Figure 12E The results show that peritoneal thickness was measured using Masson's trichrome staining and compared between groups. Peritoneal wall thickening due to peritoneal fibrosis was observed, and peritoneal thickness was significantly reduced in the AAV-miR-29b-treated group. "**" in the figure indicates p < 0.05.

[0211] As described above, the AAV-miR-29b described in this example is believed to be effective in preventing postoperative peritoneal seeding recurrence, even in pancreatic cancer, a cancer with particularly high tissue permeability and a high risk of peritoneal seeding. Therefore, AAV-miR-29b is expected to have similar effects in other cancer types that can cause peritoneal seeding.

[0212] (Therapeutic effect of combined use with anticancer drugs)

[0213] As described above, the preventive effect on peritoneal seeding was demonstrated in gastric cancer and pancreatic cancer models, thus confirming the therapeutic effect in the state where peritoneal seeding already exists at the time of diagnosis, that is, in the advanced stage of peritoneal seeding.

[0214] Specifically, the effects of AAV-miR29b in this example were studied in combination with intraperitoneal chemotherapy, which was conducted as a clinical trial at limited facilities. More specifically, it was administered in combination with paclitaxel, an anticancer agent used for intraperitoneal chemotherapy against peritoneal implants of gastric and pancreatic cancer.

[0215] Figure 13A is a conceptual diagram showing the experiment.

[0216] In this experiment, 5×10 5 Then, on day 7, 5×10 10 vg of AAV-DJ-miR-29b was administered simultaneously with 200 μg of paclitaxel (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., catalog number 167-28166) at a conventional dose (first dose). On day 14, 200 μg of paclitaxel was administered (second dose). Then, on day 21, the mice were sacrificed, and the formation of peritoneal implants was assessed by counting the number of peritoneal implant nodules on the mesentery. In other words, AAV-miR-29b was administered only once, while paclitaxel was administered multiple times.

[0217] Figure 13B Photos of the mesentery of each group are shown. "No treatment" indicates the case where only cancer cells were administered without AAV. "AAV-DJ-NC" indicates the negative control group where only the AAV-DJ vector was administered. "AAV-DJ-miR-29b" indicates the group where the AAV-DJ-miR-29b of this example was administered. "Mock" indicates the group where the paclitaxel solvent was administered. The combination with paclitaxel "PTX (200 μg)" is shown as each group.

[0218] Figure 13C The results of measuring the number of mesenteric implant nodules after 21 days are shown.

[0219] The group administered AAV-miR-29b showed a significant decrease in the number of peritoneal nodules. "*" in the figure indicates p < 0.05.

[0220] Based on the above results, the AAV-miR-29b involved in this embodiment is expected to inhibit or prevent the formation and progression of peritoneal implants not only in the prevention of peritoneal implants, but also in the treatment of already formed peritoneal implants, even when used in combination with anticancer drugs.

[0221] In addition, the configuration and operation of the above-mentioned embodiment are merely examples, and it is needless to say that they can be implemented with appropriate changes without departing from the scope of the present invention.

[0222] The therapeutic agent of the present invention is a peritoneal seeding inhibitor or preventive drug that can be expected to cure peritoneal seeding patients with poor prognosis with a single administration. It can provide a peritoneal seeding inhibitor as a therapeutic agent and can be used industrially.

Claims

1. A peritoneal implantation inhibitor, characterized in that It contains an adeno-associated virus vector carrying miR-29b.

2. The peritoneal implantation inhibitor according to claim 1, wherein The serotype of the adeno-associated virus vector includes one selected from the group consisting of AAV1, AAV2, AAV4, AAV5, AAV9 and AAV-DJ.

3. The peritoneal implantation inhibitor according to claim 2, wherein The serotype of the adeno-associated virus vector is, For humans, it is AAV1, AAV2, AAV5, or AAV-DJ; For mice, this is AAV1, AAV2, AAV4, AAV5, AAV9, or AAV-DJ.

4. The peritoneal implantation inhibitor according to claim 1, wherein The cells that constitute the peritoneal cavity are caused to express miR-29b, thereby treating or preventing peritoneal implantation.

5. The peritoneal implantation inhibitor according to claim 1, wherein The adeno-associated virus vector, Inhibits mesothelial-mesenchymal transition of peritoneal mesothelial cells and inhibits peritoneal fibrosis.

6. The peritoneal implantation inhibitor according to claim 1, wherein The adeno-associated virus vector, Administered during or after tumor surgery.

7. The peritoneal implantation inhibitor according to claim 1, wherein The adeno-associated virus vector, Administer directly into the abdominal cavity.

8. The peritoneal implantation inhibitor according to claim 1, wherein The adeno-associated virus vector, Used in combination with anticancer drugs.

9. A method for inhibiting peritoneal implantation, characterized in that: By carrying an adeno-associated virus vector carrying miR-29b, The cells constituting the peritoneal cavity are made to express miR-29b.

10. A method for preventing peritoneal implantation, characterized in that: By carrying an adeno-associated virus vector carrying miR-29b, The cells constituting the peritoneal cavity are made to express miR-29b.

11. The method for preventing peritoneal implantation according to claim 10, wherein: Used in combination with anticancer drugs.

12. A method for treating peritoneal implantation in animals other than humans, characterized in that: It uses an adeno-associated virus vector carrying miR-29b. The cells constituting the peritoneal cavity are made to express miR-29b.

Citation Information

Patent Citations

  • Attenuated simple herpesvirus

    JP2002218975A